[1] Ribatti D. A historical PersPective on milestones in multiPle myeloma research[J].Eur J Haematol,2018, 100(3): 221-228. [2] Landgren O. Shall we treat smoldering multiPle myeloma in the near future[J].Hematology Am Soc Hematol Educ Program,2017, 2017(1): 194-204. [3] Leleu X, Gay F, Flament A,et al. Incidence of neutroPenia and use of granulocyte colony-stimulating factors in multiPle myeloma: is current clinical Practice adequate[J].Ann Hematol,2018, 97(3): 387-400. [4] 中国医师协会血液科医师分会. 中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志, 2015, 54(12): 1066-1068. [5] Wu XY, Shi JM, Tao Y, et al.Diagnostic Value of IGF-I, beta2-MG and SF for Patients with MultiPle Myeloma and Their RelationshiP with Clinical Staging[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2018, 26(3): 802-806. [6] Fan L, Fu D, Zhang J, et al. Prognostic Significance of Blood Transfusion in Newly Diagnosed MultiPle Myeloma Patients without Autologous HematoPoietic Stem Cell TransPlantation[J].Biomed Res Int,2017, 2017: 5462087. [7] Song A, Eo W, Kim S, et al. Significance of serum ferritin as a Prognostic factor in advanced hePatobiliary cancer Patients treated with Korean medicine: a retrosPective cohort study[J].2018, 18(1): 176. [8] Laribi K, Bolle D, Alani M, et al. Prognostic imPact of elevated Pretreatment serum ferritin in Patients with high-risk MDS treated with azacitidine[J].ExP Hematol,2018, 65: 34-37. [9] Zhang M, He J, Liu Z, et al. Anti-beta(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiPle myeloma by inhibiting autoPhagy[J].Oncotarget, 2015, 6(11): 8567-8578.
2019, Vol. 36 
